Does the alignment of a replacement artificial heart valve in the same direction as the patient's own heart valve affect outcomes in aortic valve implantation? A feasibility study

Submission date	Recruitment status No longer recruiting	Prospectively registered		
07/03/2023		Protocol		
Registration date 20/04/2023	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 17/01/2025	Condition category Circulatory System	[] Individual participant data		
11/01/2023				

Plain English summary of protocol

Background and study aims

Aortic valve stenosis is a type of heart valve disease in which the valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. If symptoms become severe it will probably need surgery to replace the valve. A minimally invasive way of replacing a heart valve is through what is known as a transcatheter aortic valve implantation (TAVI) procedure. Currently, during a TAVI procedure, the new valve is not placed in the exact orientation of the old valve because it is not sure if this is possible. Part of this study is to try and see if the new valve can be put in the exact position of the old valve and if this will have an effect on how the valve functions. It is also postulated that orientating the valve in this way will make it easier to access the heart arteries if it is needed in future for any reason.

Who can participate?

Patients with severe aortic stenosis undergoing TAVI as decided by a structural heart multidisciplinary team, who are aged between 70 and 100 years old and are considered clinically able to undergo all the procedures necessary for the intervention.

What does the study involve?

Patients referred for either outpatient or inpatient TAVI will be approached in the first instance by their clinical team. If the patient agrees to be approached by the research team, then this will take place. If informed consent is provided by the patient they will attend the TAVI procedure in the normal way. During the procedure, the replacement heart valve will be orientated in the same way as the patient's own aortic valve. At the end of the TAVI, access to the heart arteries will be checked by catheters which are routinely used for heart artery angiograms and no dye will be injected. Overall the procedure should take no more than 10 minutes more than a standard TAVI procedure. A month later a return visit and CT scan checking the heart and arteries, will take place and this visit will take approximately 30 minutes.

What are the possible benefits and risks of participating?

It is unknown whether there will be an immediate benefit of taking part in the study beyond that expected from having your aortic valve replaced. However, the results of this study may benefit future patients having TAVI as it could improve our technique and knowledge of this procedure. There is a benefit of having the heart arteries assessed which may influence the patient's treatment. It is not believed that there are additional risks of taking part in the study over and above those involved with a standard TAVI procedure. However, there will be a CT scan after the TAVI which is one more scan than if not taking part.

Where is the study run from?
The Royal Sussex County Hospital Brighton (UK)

When is the study starting and how long is it expected to run for? March 2022 to September 2023

Who is funding the study? Terumo UK Ltd (UK)

Who is the main contact?

Dr Christopher Pavitt, christopher.pavitt@nhs.net (UK)

Contact information

Type(s)

Principal Investigator

Contact name

Dr Christopher Pavitt

ORCID ID

http://orcid.org/0000-0001-5067-8248

Contact details

Clinical Research Facility
2nd Floor Sussex House
1 Abbey Road
Brighton
United Kingdom
BN2 1ES
+44 (0)1273 696955
christopher.pavitt@nhs.net

Type(s)

Scientific

Contact name

Dr Christopher Pavitt

Contact details

Clinical Research Facility 2nd Floor Sussex House 1 Abbey Road Brighton United Kingdom BN2 1ES +44 (0)1273 696955 christopher.pavitt@nhs.net

Type(s)

Public

Contact name

Mr Duncan Fatz

Contact details

Clinical Research Facility 2nd Floor Sussex House 1 Abbey Road Brighton United Kingdom BN2 1ES +44 (0)1273 696955 duncan.fatz@nhs.net

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

309300

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

IRAS 309300

Study information

Scientific Title

Technical feasibility of neo-commissural alignment in Transcatheter Aortic Valve Implantation (TAVI): an exploratory study in patients undergoing TAVI describing procedural outcomes and effect on coronary artery access

Acronym

NeoTAVI

Study objectives

The study investigates whether aligning a replacement heart valve (TAVI) in the same orientation as the patient's own heart valve is feasible and facilitates access to coronary arteries.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/05/2022, London - Surrey Borders Research Ethics Committee (Held remotely via Teleconference/ZOOM; +44 (0)207 104 8057, (0)207 104 8104, (0)207 104 8199; surreyborders. rec@hra.nhs.uk), ref: 22/PR/0394

Study design

Interventional feasibility study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Aortic stenosis

Interventions

Traditionally aortic valve replacement for patients with severe symptomatic aortic stenosis was achieved with surgical removal and implantation of a new mechanical or tissue valve necessitating cardiopulmonary bypass. Transcatheter aortic valve implantation (TAVI) or 'keyhole' surgery of the heart in a surgical setting has become the standard of care in replacing a diseased aortic valve in patients deemed a high or medium risk for conventional open surgical replacement, and recent data and guideline recommendations have extended its use to all surgical risk groups. Pre-procedural planning is of paramount importance and computer tomography (CT) has become the imaging modality of choice due to its high temporal and spatial resolution, and its ability to accurately delineate vascular structures. In this regard, the optimum vascular access route can be identified, and CT allows the operator to reliably measure the aortic root and size the TAVI valve accordingly. Evidence has shown that the use of CT has reduced procedural complication rates, such as aortic rupture, valve embolization and post-implant paravalvular leak.

Current practice is to implant the TAVI valve at a pre-determined depth, but unlike in surgical aortic valve replacement (AVR) in which the valve commissures are aligned to the native valve, the orientation and alignment of the TAVI valve is not routinely taken into consideration or deemed clinically necessary. There is growing evidence that achieving neo-commissural alignment with TAVI may improve valve haemodynamics and reduce valve hypo-attenuated

leaflet thrombosis (HALT), both of which may impact valve function. Furthermore, it may improve coronary access in patients requiring coronary artery intubation and facilitate repeat TAVI. Coronary access post-TAVI is attracting attention and is of particular importance as the number of TAVI implants grows and extends to younger patients who are more likely to require coronary intervention after valve replacement.

This single-arm, non-randomised study involves TAVI. Patients will be recruited for the study through the normal waiting list for aortic valve implantation at the University Hospitals Sussex NHS Foundation Trust. The team conducting the TAVI procedure are professors, consultants or specialised registrars in cardiology and electrophysiology. They are all registered with the GMC and have current Good Clinical Practice certification as well as training conforming to all the relevant standard operating procedures of the University Hospitals Sussex NHS Foundation Trust.

Intervention Type

Procedure/Surgery

Primary outcome measure

- 1. TAVI valve alignment compared to patient's own aortic valve measured using cardiac-CT focusing on calculating the optimum commissural alignment during surgery
- 2. Coronary access using standard diagnostic catheters measured using CT-fractional flow reserve before and after the TAVI procedure

Secondary outcome measures

Computational fluid dynamics assessment of aortic blood flow measured using CT-fractional flow reserve before and after the TAVI procedure

Overall study start date

07/03/2022

Completion date

22/09/2023

Eligibility

Key inclusion criteria

Patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) as decided by the structural heart multi-disciplinary team (MDT)

Participant type(s)

Patient

Age group

Adult

Lower age limit

70 Years

Upper age limit

100 Years

Sex

Both

Target number of participants

30

Total final enrolment

30

Key exclusion criteria

- 1. Lack of vascular access to permit TAVI
- 2. Transaxillary or transcaval vascular access
- 3. Patient unable to undergo required post-TAVI CT-scan
- 4. Patient unable to give informed consent
- 5. Aged <70 or >100 years old
- 6. Decreased renal function eGFR <30ml/min
- 7. Pregnancy

Date of first enrolment

07/07/2022

Date of final enrolment

07/09/2023

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Royal Sussex County Hospital

Eastern Road Brighton United Kingdom BN2 5BE

Sponsor information

Organisation

University Hospitals Sussex NHS Foundation Trust

Sponsor details

Clinical Research Facility 2nd Floor Sussex House 1 Abbey Road Brighton England United Kingdom BN2 1ES +44 (0)1273696955 scott.harfield@nhs.net

Sponsor type

Hospital/treatment centre

Website

https://www.uhsussex.nhs.uk/

ROR

https://ror.org/03wvsyq85

Funder(s)

Funder type

Industry

Funder Name

Terumo UK Ltd

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

07/10/2024

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Other unpublished results			17/01/2025	No	No